PC
PRTK

Polar Capital’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

Polar Capital’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-59,230
Closed -$824K – 275
2016
Q2 		$824K Buy
+59,230
New +$872K 0.02% 247

Other funds holding PRTK

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Polar Capital's PRTK Position: Q3 2016 in Review

Polar Capital sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2016, closing a stake of 59,230 shares — an estimated $824K sold.

Polar Capital first reported a position in PRTK in Q2 2016 and held it in 1 quarter. The position peaked at $824K in Q2 2016. 86 funds tracked by Wall St. Rank hold PRTK as of Q3 2016.

  • Polar Capital reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
  • Polar Capital sold 59,230 Paratek Pharmaceuticals, Inc. shares in Q3 2016, an estimated $824K.
  • Polar Capital first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2016 and held it in 1 quarter.
  • Polar Capital's Paratek Pharmaceuticals, Inc. position peaked at $824K in Q2 2016.
  • 86 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2016.

Based on Polar Capital's 13F filing for Q3 2016, filed 14 Nov 2016.